Hoʻokahi honua hoʻokahi hakakā
─ ʻO ka launa pū ʻana o ka honua e kūkulu i kahi kaiāulu honua o ka hopena maʻamau e pane ana i nā pilikia maʻi maʻi COVID-19
ʻO ka novel coronavirus e lele ana ma ka honua holoʻokoʻa ua hopena i kahi pilikia maʻi maʻi COVID-19 honua.ʻAʻohe palena o ka novel coronavirus, ʻaʻohe ʻāina e mālama ʻia mai kēia kaua kūʻē iā COVID-19.I ka pane ʻana i kēia maʻi maʻi COVID-19 i ka honua holoʻokoʻa, ke hāʻawi nei ʻo Liming Bio-Products Corp i nā haʻawina e kākoʻo i ka pono o kā mākou kaiāulu honua.
Ke alo nei ko mākou honua i ka hopena i ʻike ʻole ʻia o ka maʻi maʻi coronavirus novel 2019 (COVID-19) maʻi maʻi.I kēia lā, ʻaʻohe lāʻau lapaʻau kūpono no ka mālama ʻana i kēia maʻi.Eia nō naʻe, ua hoʻomohala ʻia nā hoʻokolohua diagnostic he nui no ka ʻike ʻana o COVID-19.Hoʻokumu ʻia kēia mau hoʻokolohua ma nā ʻano molecular a serological paha e ʻike ai i ka novel coronavirus specific nucleic acid or antibody biomarkers.I ka hiki ʻana o COVID-19 i kahi kūlana maʻi maʻi, he mea koʻikoʻi ka ʻike mua ʻana o ka maʻi coronavirus novel i ka loiloi ʻana i ka hoʻolaha ʻana o ka maʻi a loaʻa iā ia, akā ʻaʻole i loaʻa kahi hōʻike kūpono no ka hoʻohana honua.Pono mākou e ʻike i nā hoʻokolohua hiki ke hoʻohana ʻia no ka nānā ʻana, ka maʻi ʻana, a me ka nānā ʻana i ka maʻi COVID-19, a he aha kā lākou mau palena.He mea koʻikoʻi ke ʻano o ka hoʻohana ʻana i kēia mau mea hana ʻepekema a kōkua i ka ʻike a me ka mālama ʻana i ka puka ʻana mai o kēia maʻi e laha wikiwiki a nui.
ʻO ke kumu o ka ʻike ʻana i ka novel coronavirus ʻo ia ka hoʻoholo inā he kanaka i loaʻa i ka maʻi COVID-19 a i ʻole kahi mea lawe asymptotic e hoʻolaha mālie i ka maʻi, e hāʻawi i ka ʻike koʻikoʻi e alakaʻi i ka hoʻoholo ʻana no ka mālama lapaʻau.Ua hōʻike ʻia nā haʻawina mua e pili ana ka 70% o nā hoʻoholo lapaʻau i nā hopena hoʻokolohua.Ke hoʻohana ʻia nā ʻano ʻike ʻokoʻa, ʻokoʻa nā koi o nā kit reagent detection.
Kiʻi 1
Kiʻi 1:ʻO ke kiʻikuhi e hōʻike ana i nā pae koʻikoʻi o nā pae biomarker maʻamau i ka wā maʻamau o ka maʻi COVID-19.Hōʻike ka X-axis i ka helu o nā lā o ka maʻi, a ʻo ka Y-axis e hōʻike i ka viral load, ka ʻike o nā antigens, a me ka neʻe ʻana o nā antibodies i nā manawa like ʻole.E pili ana ka Antibody i nā antibodies IgM a me IgG.Hoʻohana ʻia ka RT-PCR a me ka ʻike antigen e ʻike i ka hele ʻana a i ʻole ka puka ʻana o ka coronavirus novel, ʻo ia ka hōʻike pololei no ka ʻike mua ʻana o ka maʻi.I loko o hoʻokahi pule o ka maʻi viral, makemake ʻia ka ʻike PCR, a i ʻole ka ʻike antigen.Ma hope o ka maʻi coronavirus hou ma kahi o 7 mau lā, ua hoʻonui nui ʻia ka antibody IgM e kūʻē i ka coronavirus novel i loko o ke koko o ka mea maʻi, akā pōkole ka lōʻihi o ke ola ʻana, a ua emi koke kona ʻike.ʻO ka ʻokoʻa, ʻike ʻia ka antibody IgG i ka maʻi maʻi ma hope, ma kahi o 14 mau lā ma hope o ka maʻi maʻi.Piʻi mālie ka manaʻo IgG, a hoʻomau i kahi manawa lōʻihi i ke koko.No laila, inā ʻike ʻia ka IgM i loko o ke koko o ka mea maʻi, ʻo ia hoʻi, ua loaʻa hou ka maʻi virus, ʻo ia ka hōʻailona maʻi mua.Ke ʻike ʻia ka antibody IgG i loko o ke koko o ka mea maʻi, ʻo ia ke ʻano o ka maʻi viral no kekahi manawa.Ua kapa ʻia ʻo ia ka maʻi hope a i ʻole ka maʻi mua.ʻIke pinepineʻia i nā maʻi i loko o ka manawa ho'ōla.
ʻO nā biomarkers o ka coronavirus novel
ʻO ka novel coronavirus kahi maʻi RNA, i haku ʻia me nā protein a me nā waikawa nucleic.Hoʻopili ka maʻi i ke kino hoʻokipa (kanaka), komo i nā cell ma o ka pūnaewele hoʻopaʻa ʻana e pili ana i ka receptor ACE2, a hana hou i loko o nā pūnaewele hoʻokipa, e hoʻoneʻe ai ka ʻōnaehana pale kanaka i nā mea hoʻouka kaua a hana i nā antibodies kikoʻī.No laila, hiki ke hoʻohana ʻia ka vial nucleic acids a me nā antigens, a me nā antibodies kūikawā e kūʻē i ka coronavirus novel ma ke ʻano he biomarkers kikoʻī no ka ʻike ʻana i ka novel coronavirus.No ka ʻike ʻana i ka waikawa nucleic, ʻo ka ʻenehana RT-PCR ka mea maʻamau i hoʻohana ʻia, ʻoiai ke hoʻohana pinepine ʻia nā ʻano serological no ka ʻike ʻana i nā antibodies kikoʻī coronavirus.I kēia manawa, aia nā ʻano hana hoʻāʻo i hiki iā mākou ke koho no ka hoʻāʻo ʻana i ka maʻi COVID-19 [1].
Nā loina kumu o nā ʻano hoʻāʻo nui no ka coronavirus novel
Nui nā hoʻokolohua diagnostic no COVID_19 i kēia manawa, me nā pahu hoʻāʻo hou aʻe e loaʻa ana ka ʻae ʻia ma lalo o ka mana hoʻohana pilikia i kēlā me kēia lā.ʻOiai ke puka mai nei nā hoʻokolohua hou me nā inoa like ʻole a me nā ʻano like ʻole, ʻo nā hoʻokolohua COVID_19 i kēia manawa ke hilinaʻi nui nei i nā ʻenehana nui ʻelua: ka ʻike ʻana i ka waikawa nucleic no ka RNA viral a me nā immunoassays serological e ʻike i nā antibodies kikoʻī viral (IgM a me IgG).
01. ʻImi ʻakika nucleic
Reverse transcription-polymerase chain reaction (RT-PCR), loop-mediated isothermal amplification (LAMP), a me next-generation sequencing (NGS) ʻo ia nā ala nucleic acid maʻamau no ka ʻike ʻana i ka novel coronavirus RNA.ʻO RT-PCR ka ʻano hoʻāʻo mua no COVID-19, i ʻōlelo ʻia e ka World Health Organization (WHO) a me ka US Center for Disease Control and Prevention (CDC).
02.Serological antibody ike
ʻO ka Antibody kahi protein pale i hana ʻia i loko o ke kino o ke kanaka e pane ai i ka maʻi maʻi.ʻO ka IgM kahi ʻano antibody mua a ʻo IgG kahi ʻano antibody hope.Hoʻomaʻamaʻa pinepine ʻia ka serum a i ʻole plasma sample no ka loaʻa ʻana o nā ʻano IgM a me IgG kikoʻī o ka antibody no ka loiloi ʻana i nā pae acute a convalescent o ka maʻi COVID-19.ʻO kēia mau ʻano hana ʻike e pili ana i ka antibody me ka colloidal gold immunochromatography assay, latex a fluorescent microsphere immunochromatography, enzyme-linked immunosorbent assay (ELISA), a me chemiluminescence assay.
03.Viral antigen ike
ʻO Antigen kahi hale ma luna o ka maʻi i ʻike ʻia e ke kino o ke kanaka e hoʻoulu i ka ʻōnaehana pale pale e hana i nā antibodies e hoʻomaʻemaʻe i ka maʻi mai ke koko a me nā ʻiʻo.Hiki ke huli ʻia a ʻike ʻia kahi antigen viral ma ka hoʻohana ʻana i ka immunoassay.E like me ka viral RNA, aia nā antigens viral i loko o ka ʻōpū hanu o ka poʻe i maʻi a hiki ke hoʻohana ʻia e ʻike i ka maʻi acute-phase o ka maʻi COVID-19.No laila, ʻōlelo pinepine ʻia e hōʻiliʻili i nā specimens hanu kiʻekiʻe e like me ka saliva, nasopharyngeal a me nā oropharyngeal swabs, deep cough sputum, bronchoalveolar lavage fluid (BALF) no ka hoʻāʻo antigen mua.
Ke koho ʻana i nā ala hoʻāʻo no ka coronavirus novel
ʻO ke koho ʻana i kahi ʻano hoʻāʻo e pili ana i nā kumu he nui, me ka hoʻonohonoho ʻana i ka maʻi, ka hoʻāʻo ʻana i ka maikaʻi o ka maikaʻi, ka manawa huli, nā kumukūʻai hoʻāʻo, nā ʻano hōʻiliʻili laʻana, nā koi ʻenehana limahana limahana, nā lako a me nā pono lako.ʻO ka ʻike ʻana i nā ʻakika nucleic a i ʻole nā antigens viral e hāʻawi i nā hōʻike pololei o ka hele ʻana o nā maʻi a hōʻoia i ka maʻi o ka maʻi coronavirus novel.ʻOiai he nui nā ala no ka ʻike antigen, ʻoi aku ka haʻahaʻa o ko lākou ʻike ʻana i ka novel coronavirus ma mua o ka RT-PCR amplification.ʻO ka hoʻāʻo ʻana i ka antibody ka ʻike ʻana i nā antibodies anti-virus i hana ʻia i loko o ke kino o ke kanaka, e lohi ana i ka manawa a ʻaʻole hiki ke hoʻohana pinepine ʻia no ka ʻike mua ʻana i ka wā o ka maʻi maʻi.Hiki ke ʻokoʻa ka hoʻonohonoho ʻana i nā noi ʻike, a ʻokoʻa paha nā wahi hōʻiliʻili laʻana.No ka ʻike ʻana i nā ʻakika nucleic viral a me nā antigens, pono e hōʻiliʻili ʻia ka specimen i loko o ka ʻōpū hanu kahi e loaʻa ai ka maʻi, e like me nā swabs nasopharyngeal, nā ʻōpala oropharyngeal, sputum, a i ʻole bronchoalveolar lavage fluid (BALF).No ka ʻike ʻana ma muli o ka antibody, pono e hōʻiliʻili ʻia a nānā ʻia ke koko no ka loaʻa ʻana o kahi anti-virus antibody (IgM/IgG).Eia nō naʻe, hiki i nā hopena hoʻāʻo antibody a me ka nucleic acid ke hoʻohui i kekahi i kekahi.No ka laʻana, inā ʻo ka hopena hoʻāʻo ka nucleic acid-negative, IgM-negative akā IgG-positive, hōʻike kēia mau hopena ʻaʻole lawe ka mea maʻi i ka maʻi i kēia manawa, akā ua hoʻōla ʻia mai ka maʻi coronavirus novel.[2]
ʻO nā pono a me nā hemahema o nā hoʻokolohua coronavirus hou
I ka Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version7) (Hoʻokuʻu ʻia e National Health Commission & State Administration of Traditional Chinese Medicine ma Malaki 3, 2020), ua hoʻohana ʻia ka hoʻāʻo nucleic acid ma ke ʻano he kumu maʻamau gula no ka maʻi o ka puke. ka maʻi coronavirus, ʻoiai ʻo ka hoʻāʻo ʻana i ka antibody e noʻonoʻo ʻia ʻo ia kekahi o nā ala hōʻoia no ka maʻi maʻi.
Nā ʻike pathogen a me ka serological
(1) Nā ʻike ʻino: Hiki ke ʻike ʻia ka ʻakika nucleic coronavirus hou ma nā swabs nasopharyngeal, sputum, nā mea huna o ka ʻōpū hanu haʻahaʻa, ke koko, nā feces a me nā mea hoʻohālike e hoʻohana ana i nā ala RT-PCRand/a i ʻole NGS.ʻOi aku ka pololei inā loaʻa nā specimens mai ka ʻōpū hanu haʻahaʻa (ka ʻūhā a i ʻole ka ʻāpana ea).Pono e waiho ʻia nā hōʻailona no ka hoʻāʻo ʻana ma hope o ka hōʻiliʻili ʻana.
(2) Nā ʻike serological: ʻike ʻia ka IgM kikoʻī o ka NCP virus ma kahi o 3-5 mau lā ma hope o ka hoʻomaka ʻana;Loaʻa ka IgG i kahi titration o ka liʻiliʻi o 4 mau piʻi i ka wā o ka convalescence i hoʻohālikelike ʻia me ka pae acute.
Eia nō naʻe, ʻo ke koho ʻana i nā ʻano hoʻāʻo e pili ana i nā wahi kikoʻī, nā hoʻoponopono olakino, a me nā hoʻonohonoho lapaʻau.Ma USA, ua hoʻopuka ka NIH i nā alakaʻi lapaʻau ʻo Coronavirus Disease 2019 (COVID-19) (Site Updated: April 21,2020) a ua hoʻopuka ka FDA i ke kulekele no nā hoʻāʻo diagnostic no ka maʻi coronavirus-2019 i ka wā o ka Public Health Emergency (i hoʻopuka ʻia ma Malaki 16,2020. ), kahi i koho ʻia ai ka hoʻāʻo serological o nā antibodies IgM/IgG ma ke ʻano he hōʻike hōʻike.
ʻAno ʻImi ʻAka Nucleic
ʻO RT_PCR kahi hoʻāʻo nucleic acid koʻikoʻi i hoʻolālā ʻia e ʻike inā aia ka novel coronavirus RNA i loko o ka hanu a i ʻole nā mea hoʻohālike ʻē aʻe.ʻO kahi hopena hoʻāʻo PCR maikaʻi ʻo ia ka loaʻa ʻana o ka novel coronavirus RNA i ka laʻana e hōʻoia i ka maʻi COVID-19.ʻAʻole manaʻo ka hopena o ka hoʻāʻo PCR maikaʻi ʻole i ka loaʻa ʻole o ka maʻi maʻi no ka mea hiki ke hoʻopilikia ʻia e ka maikaʻi ʻole o ka laʻana a i ʻole ka manawa maʻi i ka manawa hoʻōla, etc.ʻOiai he hoʻāʻo koʻikoʻi loa ka RT-PCR, he nui nā hemahema.Hiki i nā ho'āʻo RT-PCR ke hoʻoikaika i ka hana a hoʻopau i ka manawa, hilinaʻi nui i ke ʻano kiʻekiʻe o ka laʻana.He mea paʻakikī kēia no ka mea ʻaʻole ʻokoʻa ka nui o ka RNA viral ma waena o nā maʻi like ʻole akā hiki ke ʻokoʻa i loko o ka mea maʻi hoʻokahi ma muli o nā manawa i hōʻiliʻili ʻia ai ka laʻana a me nā pae maʻi a i ʻole ka hoʻomaka ʻana o nā hōʻailona maʻi.Pono ka ʻike ʻana i ka coronavirus novel i nā specimen kiʻekiʻe i loaʻa ka nui o ka RNA viral intact.
Hiki paha i ka ho'āʻo RT-PCR ke hāʻawi i ka hopena maikaʻi ʻole (false negative) no kekahi mau maʻi i loaʻa i ka maʻi COVID-19.E like me kā mākou e ʻike ai, aia nā wahi maʻi nui o ka novel coronavirus ma ka māmā a me ka ʻōpū hanu haʻahaʻa, e like me ka alveoli a me ka bronchi.No laila, ʻo ka sputum specimen mai kahi ʻū hohonu a i ʻole ka bronchoalveolar lavage fluid (BALF) i manaʻo ʻia he kiʻekiʻe loa ka naʻau no ka ʻike viral.Eia nō naʻe, ma ka hoʻomaʻamaʻa lapaʻau, ʻohi pinepine ʻia nā laʻana mai ka ʻōpū hanu luna ma o ka hoʻohana ʻana i nā swabs nasopharyngeal a i ʻole oropharyngeal.ʻAʻole ʻoluʻolu wale ka ʻohi ʻana i kēia mau hiʻohiʻona no nā poʻe maʻi akā pono pū kekahi i nā limahana i hoʻomaʻamaʻa kūikawā.No ka hoʻemi ʻana i ka hōʻemi ʻana a i ʻole ka maʻalahi o ka laʻana, i kekahi manawa hiki ke hāʻawi ʻia i nā mea maʻi i kahi swab waha a ʻae iā lākou e lawe i kahi laʻana mai ka buccal mucosa a i ʻole ke alelo e swabbing iā lākou iho.Me ka lawa ʻole o ka RNA viral, hiki i ka RT-qPCR ke hoʻihoʻi i kahi hopena hoʻāʻo hewa ʻole.Ma ka mokuʻo Hubei, Kina, ua hōʻike ʻia ka naʻau RT-PCR i ka ʻike mua ʻana ma kahi o 30% -50% wale nō, me ka awelika o 40%.ʻO ka helu kiʻekiʻe o ka false-negative ma muli o ka lawa ʻole o ka laʻana.
Eia kekahi, pono ka ho'āʻo RT-PCR i nā limahana i hoʻomaʻamaʻa nui ʻia e hana i nā ʻanuʻu hoʻoiho RNA paʻakikī a me ke kaʻina hana PCR amplification.Pono nō hoʻi i kahi kiʻekiʻe o ka pale biosafety, kahi hale hoʻokolohua kūikawā, a me ka mea hana PCR manawa maoli.Ma Kina, pono e hana ʻia ka hoʻāʻo RT-PCR no ka ʻike ʻana i ka COVID-19 i loko o nā laboratories biosafety level 2 (BSL-2), me ka pale o nā limahana e hoʻohana ana i ka hana biosafety level 3 (BSL-3).Ma lalo o kēia mau koi, mai ka hoʻomaka ʻana o Ianuali a hiki i ka hoʻomaka ʻana o Pepeluali 2020, hiki ke ʻike i ka nui o ka hale hana CDC o Kina Wuhan i kahi mau haneli mau hihia i kēlā me kēia lā.ʻO ka maʻamau, ʻaʻole pilikia kēia i ka hoʻāʻo ʻana i nā maʻi maʻi ʻē aʻe.Eia nō naʻe, i ka wā e pili ana i kahi maʻi maʻi honua e like me COVID-19 me nā miliona o ka poʻe e hoʻāʻo ʻia, lilo ʻo RT-PCR i mea koʻikoʻi ma muli o kāna mau koi no nā hale hana kūikawā a i ʻole nā mea hana ʻenehana.Hiki i kēia mau hemahema ke kaupalena i ka RT-PCR e hoʻohana ʻia ma ke ʻano he mea hana pono no ka nānā ʻana, a hiki ke alakaʻi i ka lohi i nā hōʻike o nā hopena hoʻāʻo.
Ke ala ʻike antibody serological
Me ka holomua o ka papa maʻi, ʻoi loa i ka waena a me ka hopena hope, ʻoi loa ka kiʻekiʻe o ka ʻike antibody.Ua hōʻike ʻia kahi noiʻi ma Wuhan Central South Hospital e hiki ke piʻi ka nui o ka antibody detection rate ma mua o 90% i ke kolu o ka pule o ka maʻi COVID-19.Eia kekahi, ʻo ka antibody ka huahana o ka pane kūlohelohe kanaka e kūʻē i ka coronavirus novel.Hāʻawi ka hōʻike antibody i nā pono he nui ma mua o RT-PCR.ʻO ka mea mua, hoʻāʻo ka serological antibody i maʻalahi a wikiwiki.Hiki ke hoʻohana ʻia nā hoʻāʻo ʻana o ka antibody lateral flow no ka point-of-care e hāʻawi i kahi hopena i 15 mau minuke.ʻO ka lua, ʻo ka pahuhopu i ʻike ʻia e ka hoʻāʻo serological ʻo ia ka antibody, i ʻike ʻia ʻoi aku ka paʻa ma mua o ka RNA viral.I ka wā o ka hōʻiliʻili, ka lawe ʻana, ka mālama ʻana a me ka hoʻāʻo ʻana, ʻoi aku ka paʻa o nā specimens no nā hoʻāʻo antibody ma mua o nā specimens no RT-PCR.ʻO ke kolu, no ka māhele like ʻana o ka antibody i ke kahe koko, ʻoi aku ka liʻiliʻi o ka hoʻohālikelike ʻana i ka hoʻohālikelike ʻana i ka hoʻāʻo nucleic acid.He ʻuʻuku ka nui o ka laʻana no ka hoʻāʻo antibody.No ka laʻana, lawa ka 10 microliter o ke koko manamana lima no ka hoʻohana ʻana i ka hoʻāʻo ʻana i ka antibody lateral flow test.
Ma ka laulā, koho ʻia ka hōʻike antibody ma ke ʻano he mea hoʻohui no ka ʻike ʻana i ka waikawa nucleic e hoʻomaikaʻi i ka helu ʻike o ka novel coronavirus i ka wā o nā papa maʻi.Ke hoʻohana pū ʻia ka hoʻāʻo antibody me kahi hoʻāʻo nucleic acid, hiki ke hoʻonui i ka pololei assay no ka maʻi maʻi o COVID19 ma ka hōʻemi ʻana i nā hopena hoʻopunipuni a me nā hopena maikaʻi ʻole.ʻAʻole ʻōlelo ka papa kuhikuhi hana o kēia manawa e hoʻohana i ʻelua ʻano hoʻāʻo ma ke ʻano he ʻano ʻike kūʻokoʻa akā pono e hoʻohana ʻia ma ke ʻano he ʻano hui.[2]
Kiʻi 2:ʻO ka wehewehe pololei o ka nucleic acid a me nā hopena hoʻāʻo antibody no ka ʻike ʻana i ka maʻi coronavirus hou
Kiʻi 3:Liming Bio-Products Co., Ltd. – Novel coronavirus IgM/IgG antibody dual rapid test Kit (StrongStep®ʻO SARS-CoV-2 IgM/IgG Antibody Rapid Test, Latex Immunochromatography)
Kiʻi 4:Liming Bio-Products Co., Ltd. – StrongStep®ʻO ka Novel Coronavirus (SARS-CoV-2) Multiplex Real-Time PCR kit (ʻike no ʻekolu mau genes, ka hana ʻimi fluorescent).
Nānā:Loaʻa kēia pahu PCR maʻalahi a mākaukau e hoʻohana i ka format lyophilized (ka hana maloʻo maloʻo) no ka mālama lōʻihi.Hiki ke lawe ʻia a mālama ʻia ka pahu ma ka lumi wela a paʻa no hoʻokahi makahiki.Loaʻa i kēlā me kēia paipu o ka premix nā reagents a pau e pono ai no ka hoʻonui ʻana i ka PCR, me ka Reverse-transcriptase, Taq polymerase, primers, probes, a me nā substrates dNTPs. Hiki i nā mea hoʻohana ke hoʻohui hou i ka hui ʻana me ka hoʻohui ʻana i ka wai PCR-grade me ka hoʻohālikelike a laila hoʻouka. ma luna o kahi mea hana PCR e holo i ka hoʻonui.
I ka pane ʻana i ka puka hou coronavirus, ua hana wikiwiki ʻo Liming Bio-Products Co., Ltd.He kūpono loa kēia mau pahu no ka hoʻohana ʻana no ka nānā nui ʻana i nā ʻāina a me nā ʻāina kahi e laha wikiwiki nei ka puka ʻana o ka coronavirus hou, a no ka hāʻawi ʻana i ka maʻi a me ka hōʻoia ʻana no ka maʻi COVID-19.No ka hoʻohana ʻana i kēia mau pahu ma lalo o ka Pre-notified Emergency Use Authorization (PEUA).Ua kaupalena ʻia ka hoʻāʻo ʻana i nā laboratories i hōʻoia ʻia ma lalo o nā lula o ke aupuni a i ʻole nā luna kūloko.
Ke ala ʻike antigen
1. Hoʻokaʻawale ʻia ka ʻike antigen viral i ka ʻāpana like o ka ʻike pololei e like me ka ʻike ʻana o ka nucleic acid.Ke nānā nei kēia mau ala ʻike pololei i nā hōʻike o nā pathogens viral i loko o ka specimen a hiki ke hoʻohana ʻia no ka hōʻoia hōʻoia.Eia nō naʻe, ʻo ka hoʻomohala ʻana i nā pahu ʻike antigen e pono ai ke kiʻekiʻe kiʻekiʻe o nā antibodies monoclonal me ka pili ikaika a me ka naʻau kiʻekiʻe e hiki ke ʻike a hopu i nā maʻi pathogenic.ʻOi aku ka maʻamau ma mua o ʻeono mahina e koho a koho i kahi antibody monoclonal kūpono no ka hoʻohana ʻana i ka hoʻomākaukau ʻana i ka pahu ʻike antigen.
2. I kēia manawa, aia nā reagents no ka ʻike pololei ʻana i ka novel coronavirus ma lalo o ka noiʻi a me ka hoʻomohala ʻana.No laila, ʻaʻohe pahu ʻike antigen i hōʻoia ʻia a loaʻa i ke kālepa.ʻOiai ua hōʻike mua ʻia ua hoʻomohala kahi ʻoihana diagnostic ma Shenzhen i kahi pahu ʻike antigen a hoʻāʻo ʻia ma Sepania, ʻaʻole hiki ke hōʻoia i ka hilinaʻi a me ka pololei o ka assay ma muli o ka loaʻa ʻana o nā pilikia reagent quality.I kēia lā, ʻaʻole ʻae ʻo NMPA (Kina FDA ma mua) i kahi pahu ʻike antigen no ka hoʻohana lāʻau.I ka hopena, ua kūkulu ʻia nā ʻano hana ʻike like ʻole.Loaʻa i kēlā me kēia ala kona mau pono a me nā palena.Hiki ke hoʻohana ʻia nā hopena mai nā ʻano hana like ʻole no ka hōʻoia a hoʻokō.
3. ʻO ka hana ʻana i kahi pahu hoʻāʻo COVID-19 maikaʻi e hilinaʻi nui ʻia i ka loiloi i ka wā o ka noiʻi a me ka hoʻomohala ʻana.Liming Bio-Product Co., Ltd.koi ʻia nā pahu hoʻāʻo e hoʻokō i nā kūlana hana paʻa a me nā kūlana hoʻomalu maikaʻi e hōʻoia i ka hāʻawi ʻana i nā pae kiʻekiʻe o ka hana a me ke kūlike.ʻO nā kānaka ʻepekema ma Liming Bio-Product Co., Ltd. ua ʻoi aku ma mua o iwakālua mau makahiki i ka hoʻolālā ʻana, ka hoʻāʻo ʻana, a me ka hoʻomaikaʻi ʻana i nā pahu diagnostic in vitro e hōʻoia i ka pae kiʻekiʻe o ka hana ma ka helu analytical.
I ka wā o ka maʻi maʻi COVID-19, ua kū ke aupuni Kina i ka piʻi nui ʻana o ka koi nui no nā mea pale maʻi maʻi ma nā wahi wela o ka honua.Ma ka lā 5 o ʻApelila, i ka hālāwai kūkā o ka ʻAha Moku'āina Hui Pū ʻIa a me ka Mana Mana "E hoʻoikaika i ka hoʻokele maikaʻi ʻana o nā lāʻau lapaʻau a me ka hoʻoponopono ʻana i ke kauoha o ka mākeke", ʻo Jiang Fan, kahi mea nānā mua o ka Foreign Trade Department o ke Kuhina. of Commerce, i ʻōlelo ʻia, "Ma hope, e kālele mākou i kā mākou mau hana ma nā ʻaoʻao ʻelua, ʻo ka mea mua, e wikiwiki i ke kākoʻo o nā lako olakino e pono ai e ke kaiāulu honua, a me ka hoʻomaikaʻi ʻana i ka mana maikaʻi, hoʻoponopono, a me ka hoʻokele ʻana i nā huahana. E hana mākou i ka hāʻawi ʻana o Kina i ka pane like ʻana i ka maʻi maʻi honua a kūkulu i kahi kaiāulu me kahi wā e hiki mai ana no ke kanaka.
Kiʻi 5:Ua loaʻa i ka Liming Bio-Products Co., Ltd. ka mea hou coronavirus reagent i ka palapala hoʻopaʻa inoa EU CE.
Ka palapala hanohano
Houshenshan
Kiʻi 6. Kākoʻo ʻo Liming Bio-Products Co., Ltd. i ka Halemai Mauna ʻo Wuhan Vulcan(HouShenShan) e kaua kūʻē i ka maʻi maʻi COVID-19 a ua loaʻa iā ia ka palapala hoʻohanohano o Wuhan Red Cross.ʻO ka haukapila mauna ʻo Wuhan Vulcan ka haukapila kaulana loa ma Kina e loea i ka mālama ʻana i nā maʻi maʻi COVID - 19.
Ke hoʻomau nei ka laha ʻana o ka coronavirus hou a puni ka honua, ke piʻi nei ʻo Nanjing Liming Bio-Products Co., Ltd. e kākoʻo a kōkua i nā kaiāulu o ka honua me kā mākou ʻenehana hou e hakakā i kēia hoʻoweliweli honua ʻole.ʻO ka hoʻāʻo wikiwiki ʻana i ka maʻi COVID-19 kahi ʻāpana koʻikoʻi o ka hoʻoponopono ʻana i kēia hoʻoweliweli.Ke hoʻomau nei mākou i ka hāʻawi ʻana i kahi ala koʻikoʻi ma o ka hāʻawi ʻana i nā kahua diagnostic kiʻekiʻe i nā lima o nā limahana mālama ola mua i hiki i nā poʻe ke loaʻa nā hopena hoʻokolohua koʻikoʻi e pono ai lākou.ʻO nā hana a Liming Bio-products Co., Ltd. i ke kaua kūʻē i ka maʻi maʻi COVID-19 e hāʻawi i kā mākou ʻenehana, ʻike, a me ka ʻike i nā kaiāulu honua no ke kūkulu ʻana i kahi kaiāulu honua o ka hopena.
Paʻi lōʻihi~Scan and Follow us
leka uila: sales@limingbio.com
Paena pūnaewele: https://limingbio.com
Ka manawa hoʻouna: Mei-01-2020
